Optimal regimes for local IL-2 tumour therapy

International Journal of Cancer

Volumn 66, Issue 3, 1996, Pages 400-403

  Den Otter, Willem ^a   De Groot, Jan Willem ^a   Bernsen, Monique R ^a   Heintz, A Peter M ^c   Maas, Riks ^e   Hordijk, Gerrit Jan ^d   Hill, F W Graham ^g   Klein, Wim R ^a   Ruitenberg, E Joost ^b,f   Rutten, Victor P M G ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Department of Infectious Diseases and Immunology   (Netherlands)

^c Academic Hospital   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f CENTRAL LABORATORY   (Netherlands)

^g UNIVERSITY OF ZIMBABWE   (Zimbabwe)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; LIVER METASTASIS; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

ANIMALS; CATTLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; INTERLEUKIN-2; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHOMA, DIFFUSE; MALE; MAST-CELL SARCOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; RATS; RATS, INBRED ACI; TIME FACTORS;

EID: 9344221642     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960503)66:3<400::AID-IJC22>3.0.CO;2-D     Document Type: Article

References (35)

1. BERNSEN, M.R., DULLENS, H.F.J., DEN OTTER, W. and HEINTZ, A.P.M., Chemo-immunotherapy of cancer with a combination of low-dose Cisplatin and low-dose recombinant Interleukin 2. In: F. Sharp, W.P. Mason and W. Creasmen (eds.), Ovarian cancer, 2: biology, diagnosis, and management, pp. 189-194, Chapman and Hall, London (1992).
2. BERNSEN, M.R., VAN BARLINGEN, H.J.J., VAN DER VELDEN, A.W., DULLENS, H.F.J., DEN OTTER, W. and HEINTZ, A.P.M., Dualistic effects of cis-diammine-dichloro-platinum on the anti-tumor efficacy of subsequently applied recombinant interleukin-2 therapy: a tumor-dependent phenomenon. Int. J. Cancer, 54, 513-517 (1993).
3. BRUTON, J.K. and KOELLER, J.M., Recombinant interleukin-2. Pharmacotherapy, 14, 635-656 (1994).
4. BUBENIK, J. and INDROVA, M., Cancer immunotherapy using local interleukin 2 administration. Immunol. Lett., 16, 305-309 (1987).
5. CORTESINA, G., DE STEFANI, A., GIOVARELLI, M., BARIOGLIO, M.G., CAVALLO, G.P., JEMMA, C. and FORNI, G., Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer, 62, 2482-2485 (1988).
6. DEN OTTER, W., HILL, F.W.G., KLEIN, W.R., KOTEN, J.W., STEERENBERG, P.A., DE MULDER, P.H., RHODE, C., STEWART, R., FABER, J.A.J., RUITENBERG, E.J. and RUTTEN, V.P.M.G., Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up. Cancer Immunol. Immunother., 41, 10-14 (1995).
7. DEN OTTER, W., HILL, F.W.G., KLEIN, W.R., KOTEN, J.W., STEERENBERG, P.A., DE MULDER, P.H., RUTTEN, V.P.M.G. and RUITENBERG, E.J., Low doses of interleukin-2 can cure large bovine ocular squamous-cell carcinoma. Anticancer Res., 13, 2453-2456 (1993).
8. DUBINETT, S.M., PATRONE, L., TOBIAS, J., COCHRAN, A.J., WEN, D.R. and MCBRIDE, W.H., Intratumoral interleukin-2 immunotherapy: activation of tumor-infiltrating and splenic lymphocytes in vivo. Cancer Immunol. Immunother., 36, 156-162 (1993).
9. DULLENS, H.F.J., HILGERS, J., SPIT, B.J., DE HEER, E., DE WEGER, R.A., VAN BASTEN, C.D. and DEN OTTER, W., Staging, growth properties and metastatic behaviour of a transplantable murine T-cell lymphoma. Int. J. Tiss. React., 4, 15-25 (1982).
10. FORNI, G., GIOVARELLI, M., SANTONI, A., MODESTI, A. and FORNI, M., Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity. J. Immunol., 11, 4033-4041 (1987).
11. HILL, F.W., KLEIN, W.R., HOYER, M.J., RUTTEN, V.P., KOCK, N., KOTEN, J.W., STEERENBERG, P.A., RUITENBERG, E.J. and DEN OTTER, W., Antitumor effect of locally injected low doses of recombinant human interleukin-2 in bovine vulval papilloma and carcinoma. Vet Immunol. Immunopathol., 41, 19-29 (1994).
12. HULAND, E., HULAND, H. and HEINZLR, H., Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma. J. Urol., 147, 344-348 (1992).
13. LISSONI, P., BARNI, S., ARDIZZOIA, A., CRISPINO, S., PAOLOROSSI, F., ARCHILI, C., VAGHI, M. and TANCINI, G., Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Europ. J. Cancer. 28, 92-96 (1992).
14. MAAS, R.A., DULLENS, H.F.J., DE JONG, W.H. and DEN OTTER, W., Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2. Cancer Res., 49, 7037-7040 (1989).
15. MAAS, R.A., DULLENS, H.F.J. and DEN OTTER, W., T cells and tumors. Immunol. Today. 13, 78-79 (1992a).
16. - cytotoxic T lymphocytes and macrophages. Immunobiology. 186, 214-229 (1992b).
17. MAAS, R.A., VAN WEERING, D.H., DULLENS, H.F.J. and DEN OTTER, W., Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour. Cancer Immunol. Immunother., 33, 389-394 (1991).
18. MATTIJSSEN, V., BALEMANS, L.T., STEERENBERG, P.A. and DE MULDER, P.H., Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea-pig tumors. Int. J. Cancer, 51, 812-817 (1992).
19. MATTIJSSEN, V., DE MULDER, P.H., DE GRAEFF, A., HUPPERETS, P.S., JOOSTEN, F., RUITER, D.J., BIER, H., PALMER, P.A. and VAN DEN BROEK, P., Intratumoral PEG-interleukin-2 therapy in patients with locoregionally recurrent head and neck squamous-cell carcinoma. Ann Oncol., 5, 957-960 (1994).
20. OTTOW, R.T., STELLER, E.P., SUGARBAKER, P.H., WESLEY, R.A. and ROSENBERG, S.A., Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models. Cell. Immunol., 104, 366-376 (1987).
21. PAPA, M.Z., MULE, J.J. and ROSENBERG, S.A., Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Cancer Res., 46, 4973-4978 (1986).
22. RAVAUD, A., NEGRIER, S., CANY, L., MERROUCHE, Y., LE GUILLOU, M., BLAY, J.Y., CLAVEL, M., GASTON, R., OSKAM, R. and PHILIP, T., Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. Brit. J. Cancer, 69, 1111-1114 (1994).
23. ROSENBERG, S.A. and 12 OTHERS. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl. J. Med., 313, 1485-1492 (1985).
24. RUTTEN, V.P.M.G., KLEIN, W.R., DE JONG, W.A., MISDORP, W., DEN OTTER, W., STEERENBERG, P.A., DE JONG, W.H. and RUITENBERG, E.J., Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. A pilot study. Cancer Immunol. Immunother., 30, 165-169 (1989).
25. SLEIJFER, D.T., JANSSEN, R.A., BUTER, J., DE VRIES, E.G., WILLEMSE, P.H. and MULDER, N.H., Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J. clin. Oncol., 10, 1119-1123 (1992).
26. SONE, S. and OGURA, T., Local interleukin-2 therapy for cancer, and its effector induction mechanisms. Oncology, 51, 170-176 (1994).
27. STEIS, R.G. and 13 OTHERS, Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J. clin. Oncol., 8, 1618-1629 (1990).
28. TALMADGE, J.E., PHILLIPS, H., SCHINDLER, J., TRIBBLE, H. and PENNINGTON, R., Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res., 47, 5725-5732 (1987).
29. THOMPSON, J.A., PEACE, D.J., KLARNET, J.P., KERN, D.E., GREENBERG, P.D. and CHEEVER. M.A., Eradication of disseminated murine leukemia by treatment with high dose interleukin 2. J Immunol., 137, 3675-3680 (1986).
30. VAAGE, J., Local and systemic effects during interleukin-2 therapy of mouse mammary tumors. Cancer Res., 47, 4296-4298 (1987).
31. VAAGE, J., Local interleukin 2 therapy of mouse mammary tumors of various immunogenicities. Cancer Res., 48, 2193-2197 (1988).
32. VAAGL, J., Pen-tumor interleukin-2 causes systemic therapeutic effect via interferon-gamma induction. Int. J. Cancer, 49, 598-600 (1991).
33. VELOTII, F. and 15 OTHERS, Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin 2. Cancer Res., 51, 2456-2462 (1991).
34. WHITTINGTON, R. and FAULDS, D., Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs, 46, 446-514 (1993).
35. YANG, J.C. and 16 OTHERS. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J. clin. Oncol. 12, 1572-1576 (1994).